Carisma Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 20.96 million compared to USD 16.74 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 7.61 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -1.99% | -8.64% | -49.49% |
05-09 | Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-02 | Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.49% | 61.48M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- CARM Stock
- News Carisma Therapeutics, Inc.
- Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023